33 results about "Matrix Metalloprotease" patented technology

The present invention is concerned with a protein oligomer comprising (i) at least two NC-1 monomers of collagen 18 or (ii) at least two endostatin domains of collagen 18 or (iii) at least two N-terminal peptides of the collagen 18 endostatin domain, for use in treating, ameliorating or preventing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease. The invention further relates to the mentioned protein oligomer for use for detecting and / or diagnosing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease.

The invention relates to the technical field of medicines, and provides application of pulsatilla saponin B4 in preparation of a medicine for treating osteoarthritis. The pulsatilla saponin B4 can obviously promote the expression of SOX9, which is an important cartilage specific transcription factor, and inhibit the expression of matrix metalloproteinase 13 and disintegrin and metalloproteinase 5 with platelet reaction protein motifs at the same time, thereby finally relieving the degradation of extracellular cartilage matrixes such as II-type collagen and aggregation proteoglycan. Therefore, the pulsatilla saponin B4 can inhibit cartilage degeneration and improve cartilage extracellular matrix metabolic disorder. After the pulsatilla saponin B4 is injected into the abdominal cavity of a mouse with osteoarthritis, the progress of the osteoarthritis is effectively relieved, the side effect is relatively small, and no obvious injury is caused to main organs. The pulsatilla saponin B4 is applied to treatment of osteoarthritis, new application of the pulsatilla saponin B4 is developed, and a new choice is provided for preparation of the medicine for treating osteoarthritis.

The present invention provides a method for activating matrix metalloproteinase 1 (proMMP-1) to matrix metalloproteinase 1 (MMP-1), comprising: a first incubation in which proMMP-1 is incubated in a solution containing an imidazole and / or an imidazolyl group-containing compound; and a second incubation in which the proMMP-1 subjected to the first incubation is incubated in a solution containing Ca < 2 + >. The invention also provides a kit for activating proMMP-1 into MMP-1, which comprises proMMP-1 or a solution containing proMMP-1, imidazole and / or a compound containing imidazolyl, or a solution containing imidazole and / or a compound containing imidazolyl, and a substance capable of generating calcium ions (Ca < 2 + >) or a solution containing Ca < 2 + >, which are packaged respectively. The invention also provides application of the proMMP-1 or a solution containing the proMMP-1, imidazole and / or a compound containing an imidazolyl group, or a solution containing the imidazole and / or the compound containing the imidazolyl group, and a substance capable of generating calcium ions (Ca < 2 + >) or a solution containing Ca < 2 + > in preparation of a kit for activating the proMMP-1 into the MMP-1.

The present invention provides specific matrix metalloproteinase (MMP) polypeptide inhibitors and uses thereof in treating MMP-related diseases, in particular cancer, such as breast cancer and glioblastoma.

The application provides an engineered exosome loaded with a CD63 transmembrane domain-matrix metalloproteinase fusion protein and a preparation method and application thereof. The engineered exosome is secreted by a genetically engineered mesenchymal stem cell, has a CD63 derived transmembrane domain anchored on the membrane, and has a matrix metalloproteinase (MMP) loaded on the inner side of the membrane. The fusion protein comprises, from N-terminus to C-terminus, a fourth transmembrane domain and a C-terminal cytoplasmic tail of a human CD63 protein, a flexible linker peptide, and a human MMP without a natural signal peptide. The application realizes efficient and directional loading of MMPs by using a natural biological generation path of the exosome, shields the inhibition of MMPs by metalloproteinase tissue inhibitors in a scar tissue by using the membrane of the exosome, realizes specific activation of MMPs in a target cell, degrades abnormally deposited collagen, adjusts the ratio of type I and type III collagens, and plays an anti-fibrosis and anti-scar formation role. The application also provides a preparation method of the engineered exosome and application thereof in preparation of a medicine for preventing or treating pathological scars.

The present invention belongs to the field of biomedicine technology, and more specifically, to a magnetic probe and its application in the preparation and detection of matrix metalloproteinases. The present invention provides a magnetic probe and its application in the preparation and detection of matrix metalloproteinases, the purpose of which is to utilize the hydrolysis characteristics of matrix metalloproteinases to identify specific oligopeptide sequences and cut them, prepare functionalized signal probes, and combine magnetic separation technology and commercial test strips to solve the problems of high cost, low detection sensitivity and narrow scope of application of the existing technology. The present invention utilizes the high specificity of protease hydrolysis and the high sensitivity of the test strips to the target probe to achieve sensitive detection of MMP-1, with a visual detection limit of 65.5 pg / mL, which has good anti-interference and sensitivity in the application of biological sample matrices.

The application belongs to the technical field of regenerative medicine, and particularly relates to an ASP / BFP-1 sustained-release nanofiber membrane and a preparation method and application thereof. In the initial stage of bone repair, matrix metalloproteinase-2 (MMP-2) secreted by a large number of stem cells can effectively degrade gelatin and polylysine in the nanofiber membrane coating, so as to sequentially release aspirin and bone formation peptide-1 in the drug-loaded coating. The released aspirin can control inflammation, and the bone formation peptide-1 can enhance the osteogenic potential of stem cells and guide bone tissue regeneration.

The invention relates generally to cleavable polypeptides, method of producing a cleavable moiety (CM) containing polypeptide by culturing a cell under conditions that lead to expression of the polypeptide, methods of manufacturing a cleavable moiety (CM) containing polypeptide by culturing a cell comprising a nucleic acid construct that encodes the cleavable polypeptide to express the cleavable polypeptide, and recovering the cleavable polypeptide, nucleic acids encoding the cleavable polypeptides, and vectors including the nucleic acids encoding the cleavable polypeptides.

Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Isolated polypeptides that include a cleavable moiety that is a substrate for at least one protease (e.g., MT-SP1 and / or an MMP) and isolated polypeptides that include a substrate that has a first cleavable moiety cleavable by a first protease and a second cleavable moiety cleavable by a second protease are disclosed. Activatable molecules including the isolated polypeptides are disclosed. Methods of making and using the isolated polypeptides and activatable molecules including the isolated polypeptides in a variety of therapeutic, diagnostic, and prophylactic applications are disclosed.

The invention discloses a matrix metalloproteinase MMP2 gene and application of dsRNA of the matrix metalloproteinase MMP2 gene in prevention and treatment of ladybird beetles. The dsRNA for synthesizing the matrix metalloproteinase gene MMP2 of the ladybird is injected into the body of the ladybird, so that the MMP2 gene of the ladybird can be specifically silenced, the ecdysis of the larva of the ladybird can be inhibited, the metamorphosis and development of the larva fail, then the individual death is caused, and the purpose of biological control is achieved; the method has the advantages of specificity, high efficiency and environmental protection in pest control, is a novel green pollution-free ladybird prevention and control technology, and shows a huge application prospect in prevention and control of ladybird.

The invention relates to the field of biological pharmacy, in particular to application of a regulatory factor inhibitor in preparation of a medicine for treating scapulohumeral periarthritis, and the regulatory factor inhibitor is used for inhibiting expression of interleukin 6 and / or inhibiting expression of matrix metalloproteinase 2 and matrix metalloproteinase 9. By inhibiting the expression of the regulatory factors, the activity of M1 type macrophages is inhibited, the activity of M2 type macrophages is not influenced, the development of inflammation is inhibited through an immune system, and the anti-inflammatory effect is improved.

The invention relates to the field of medicine, in particular to a biomarker for diagnosis and prognosis evaluation of ventricular arrhythmia of a patient with dilated cardiomyopathy (DCM) and application of the biomarker. Matrix metalloproteinase-9 (MMP-9), 5-hydroxytryptamine (5-HT), noradrenaline (NE) and acetylcholine (ACh) are screened to serve as a biomarker combination, and by measuring the levels of MMP-9, 5-HT, NE and ACh in plasma, whether a DCM patient is accompanied with ventricular arrhythmia or not can be effectively recognized, the severity of the condition of the patient is evaluated, and the prognosis risk of the patient is predicted. The synergistic effect of MMP-9, 5-HT, NE and ACh can complement the defects of a single index, the diagnosis efficiency is improved, particularly, high specificity is achieved for ventricular arrhythmia, and an important basis is provided for risk stratification and individualized treatment of DCM patients.

The present invention relates generally to polypeptides comprising at least a first cleavable moiety (CM1) as a substrate for at least one matrix metalloproteinase (MMP) and at least a second cleavable moiety (CM2) as a substrate for at least one serine protease (SP) or at least one cysteine protease (CP); to activatable antibodies and other larger molecules comprising these polypeptides comprising at least CM1 as a substrate for at least one MMP protease and at least CM2 as a substrate for at least one SP protease or at least one cysteine protease (CP); the present invention relates to polypeptides comprising at least CM1 as a substrate for at least one MMP protease and at least CM2 as a substrate for at least one SP protease or at least one cysteine protease (CP), and to methods of making and using these polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.

Compositions and methods for cosmetic applications are disclosed. The composition can contain ascorbic acid tetrahexyldecanol ester, phyllanthus emblica fruit extract, tocopherol and ascorbic acid. The composition may also comprise a plant amino acid. An effective amount of the composition may be applied to the skin to stimulate collagen production and lysyl oxidase activity, inhibit tyrosinase, inhibit melanogenesis and / or COX-1 activity, and inhibit matrix metalloproteinase activity in the skin.

The invention belongs to the field of biological medicine, and particularly relates to double-stranded oligonucleotide of a targeted MMP-7 gene and application of the double-stranded oligonucleotide. Specifically, provided are a double-stranded oligonucleotide agent or a salt, conjugate, composition thereof for inhibiting the expression of matrix metalloproteinase 7 (MMP-7) wherein the double-stranded oligonucleotide agent comprises one sense strand and one antisense strand forming a double-stranded region; wherein the antisense strand sequence comprises at least 15 contiguous nucleotides of the sequence shown in any one of SEQ ID NO: 1-85 and the difference is not greater than 3 nucleotides, and / or the sense strand sequence comprises at least 15 contiguous nucleotides of the sequence shown in any one of SEQ ID NO: 86-170 and the difference is not greater than 3 nucleotides. The double-strand oligonucleotide agent for inhibiting the expression of the MMP-7 or the salt thereof disclosed by the invention can obviously inhibit the expression of the MMP-7, and can be used for preventing and / or treating MMP-7 gene mediated diseases or symptoms.

The invention belongs to the technical field of biological medicines, and relates to application of a matrix metalloproteinase 8 mutant MMP8-P326V, in particular to application of the matrix metalloproteinase 8 mutant MMP8-P326V in treatment of vascular dementia and senile dementia. The matrix metalloproteinase 8 mutant MMP8-P326V is applied to treatment of the vascular dementia and the senile dementia for the first time, and experiments prove that the matrix metalloproteinase 8 mutant MMP8-P326V can improve and treat the vascular dementia and the senile dementia and effectively improve pathological phenotypes of the vascular dementia and the senile dementia. In a vascular dementia animal model, the MMP8-P326V can inhibit neuroinflammation, improve neuronal functions of vascular dementia or senile dementia and improve cognitive impairment and cognitive functions, and meanwhile, in the vascular dementia animal model, the MMP8-P326V shows dual regulation effects of inhibiting neuroinflammation and improving the cognitive functions. The invention is expected to provide a strategy for precise treatment of vascular dementia and senile dementia, and has a good application prospect.

Methods for treating chronic wounds with an amniotic fluid having a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases (TIMPs) are described. The amniotic fluid can be obtained from a female donor during a period of gestation when the concentration of endogenous TIMPs are at or near their maximum level. The methods described herein are particularly useful for promoting wound healing in chronic wounds having elevated protease activity, such as increased amounts or specific activity of matrix metalloproteinases.

The present invention relates to B-hydroxy and amino substituted carboxylic acide, which act as matrix metalloprotease inhibitor, particularly diastereomerically pure B-hydroxy carboxylic acid, corresponding processes for the synthesis of and pharmaceutical composition containing the compounds of the present invention. Compound of the present invention are useful in the treatment of various inflammatory, autoimmune and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriaasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase using the compound.

The invention discloses application of lactobacillus helveticus CCFM1440 in relieving rheumatoid arthritis, and belongs to the technical field of microorganisms. A strain of lactobacillus helveticus CCFM1440 is screened, the lactobacillus helveticus CCFM1501 can produce cell wall protease and aromatic transaminase at high yield, and has the effect of relieving rheumatoid arthritis, which is specifically reflected in that the thickness of a posterior claw of a rat with rheumatoid arthritis is reduced, and knee joint injury is improved; according to the present invention, the content of pro-inflammatory cytokines such as IL-1beta, IL-6, IL-17A and TNF-alpha in the serum of the rheumatoid arthritis rat can be reduced, the content of arthritis specific antibodies and matrix metalloproteinase in the serum of the rheumatoid arthritis rat can be reduced, the intestinal flora of the rheumatoid arthritis rat can be improved, and the abundance of the bacillus thuringiensis and the Rombout can be reduced;

The present invention belongs to the technical field of cosmetics, and particularly relates to a natural source composition having the function of inhibiting various types of matrix metalloproteinases in the skin and its uses. The composition comprises the following components: cistanche powder, american ginseng powder, polygonum orientale extract and justicia procumbens extract. The composition of the present invention can simultaneously inhibit the expression of various types of matrix metalloproteinases in immortalized keratinocytes of the skin, improve the synthesis of elastin, and inhibit the decomposition of elastase, and has no obvious side effects. The composition of the present invention can be used for preparing various cosmetics, functional foods and health products related to anti-skin aging, and has broad application prospects.

The invention relates generally to cleavable polypeptides, method of producing a cleavable moiety (CM) containing polypeptide by culturing a cell under conditions that lead to expression of the polypeptide, methods of manufacturing a cleavable moiety (CM) containing polypeptide by culturing a cell comprising a nucleic acid construct that encodes the cleavable polypeptide to express the cleavable polypeptide, and recovering the cleavable polypeptide, nucleic acids encoding the cleavable polypeptides, and vectors including the nucleic acids encoding the cleavable polypeptides.

The invention belongs to the technical field of medicines, and discloses a copper hyperplasia inhibitor for tumor chemoimmunotherapy and application of the copper hyperplasia inhibitor. The structure of the copper hyperplasia inhibitor is shown in the specification, wherein R is a copper chelating coordination group. The copper hyperplasia inhibitor can interfere with a copper hyperplasia signal channel, break the redox balance of tumor cells, trigger endoplasmic reticulum and mitochondrial stress and cause melanoma cell death. Meanwhile, the expression of matrix metalloproteinase can be down-regulated, and diffusion and metastasis of tumor cells are effectively inhibited. In addition, the copper hyperplasia inhibitor can also inhibit PHGDH expression to remodel macrophage subpopulation, promote immune stimulatory cell maturation, remodel tumor microenvironment and activate immune response to indirectly kill tumor cells, thereby enhancing the anti-tumor immune response effect. The copper hyperplasia inhibitor, namely CC, provided by the invention simultaneously has chemical treatment and immunoregulation functions, so that the problems of large action dose, poor immunotherapy effect and the like of a pure chelating agent are solved. # imgabs0 #

The invention discloses a method for modifying mesenchymal stem cells with dual-response peptide fragments and application of the mesenchymal stem cells in drug delivery. The dual response type peptide fragment (MSP-Trap) is composed of three parts: a connecting sequence sensitive to matrix metalloproteinase, a binding sequence targeting heparan sulfate, and a functional group used for NHS coupling. The MSP-Trap peptide fragment can be coupled to the surface of a mesenchymal stem cell (MSC) through NHS, and can be used as a drug carrier to realize efficient delivery of drugs. According to the invention, the MSP-Trap-MSC is further combined with a drug to form a drug-MSP-Trap-MSC compound, so that the enrichment and delivery efficiency of the drug at a diseased region is enhanced, and the MSP-Trap-MSC compound is used for treating different types of diseases.

To identify new substrates for proteases and use these substrates for a variety of therapeutic, diagnostic and prophylactic applications.SOLUTION: The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one matrix metalloprotease (MMP), to activatable antibodies and other large molecules that include the cleavable moiety that is a substrate for at least one MMP protease, and to methods of making these polypeptides that include a cleavable moiety that is a substrate for at least one MMP protease and using them for a variety of therapeutic, diagnostic and prophylactic applications.SELECTED DRAWING: Figure 1A

The invention relates generally to cleavable polypeptides, method of producing a cleavable moiety (CM) containing polypeptide by culturing a cell under conditions that lead to expression of the polypeptide, methods of manufacturing a cleavable moiety (CM) containing polypeptide by culturing a cell comprising a nucleic acid construct that encodes the cleavable polypeptide to express the cleavable polypeptide, and recovering the cleavable polypeptide, nucleic acids encoding the cleavable polypeptides, and vectors including the nucleic acids encoding the cleavable polypeptides.

The invention discloses application of CD44v9 positive M2 type macrophages in preparation of gastric adenocarcinoma diagnosis or treatment products, in the technical scheme provided by the invention, it is proved that the M2 type macrophages of CD68 + CD86-CD163 + can express CD44v9 through multiple fluorescent staining, human acute mononuclear leukemia cells (THP-1 cells) are subjected to in-vitro culture and are sequentially induced into M0 type macrophages and M2 type macrophages, and the M0 type macrophages and the M2 type macrophages can be used for diagnosing or treating gastric adenocarcinoma. Then, the expression conditions of the M0 type macrophage CD44v9 and the M2 type macrophage CD44v9 are observed, and the result shows that the M0 type macrophage and the M2 type macrophage which are induced by the THP-1 cell in vitro can express the CD44v9, and the expression level of the M2 type macrophage is higher than that of the M0 type macrophage CD44v9. Afterwards, after co-culture with gastric adenocarcinoma AGS cells in M2 macrophages infected and induced by over-expressed CD44v9 lentivirus, the proliferation, migration and invasion capabilities of the AGS cells are enhanced, and the epithelial-mesenchymal transition of the AGS cells and the expression of matrix metalloproteinases (MMP2 and MMP9) are promoted.

The application relates to the field of geriatric treatment, in particular to application of a matrix metalloproteinase inhibitor, MSAB or a pharmaceutically acceptable salt thereof, in preparation of a medicine for preventing or treating osteoarthritis cartilage injury. The application adopts the MSAB to inhibit expression of matrix metalloproteinase in chondrocytes, reduces destruction of joint cartilage structure, and achieves the effect of preventing or treating osteoarthritis.

The present invention discloses a method for detecting the activity of membrane type I matrix metalloproteinase. First, a Raman-fluorescent dual-mode probe particle is constructed using a polypeptide sequence. Then, the probe is added to a cell sample, and the specific cleavage of the polypeptide sequence by membrane type I matrix metalloproteinase causes a switch between Raman signals and fluorescent signals, realizing the visualization of the activity of membrane type I matrix metalloproteinase in cells. Finally, the Raman spectrum and fluorescent spectrum in the cells are collected, and a corresponding relationship between the signal intensity and the activity of membrane type I matrix metalloproteinase is established to achieve the purpose of semi-quantitative analysis. The Raman-fluorescent switch-type detection method adopted by the present invention can effectively reduce the interference of background signals and has the advantages of high sensitivity, good specificity, and strong reliability.

The present application provides a kind of stem cell composition for treating male erectile dysfunction and its preparation method, belong to medical technology field.Magnetic particles loaded with platelet-derived growth factor and matrix metalloproteinase are added to culture medium, amniotic membrane mesenchymal stem cells are activated, and activated amniotic membrane mesenchymal stem cells, paracrine composition and magnetic nutrient particles are obtained by separation, mixed with intercalated sustained-release drug compound and penetration activator and added to temperature-sensitive hydrogel sustained-release system to prepare stem cell composition for treating male erectile dysfunction.The stem cell composition for treating male erectile dysfunction prepared by the present application plays a role through multiple pathways, promotes angiogenesis, improves penile hemodynamics, inhibits smooth muscle cell apoptosis, regulates nerve function, enhances endothelial progenitor cell recruitment, etc., thereby more comprehensively repairing and regenerating damaged penile tissue, and has broad application prospects.